All Pulmonary Disease

  • Brown AW. Unclassifiable Interstitial Lung Disease: Time to Shrink the Black Box. Ann Am Thorac Soc. 2018 Jul;15(7):806-807.
  • King CS, Brown AW, Shlobin OA, Weir N, Libre M, Franco-Palacios D, Ahmad S, Nathan SD. Prevalence and Impact of WHO Group 3 Pulmonary Hypertension in Advanced Idiopathic Nonspecific Interstitial Pneumonia. Eur Respir J. 2018 May 17.
  • Aryal S, Nathan SD An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2018 May 8:1-14
  • Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS Kouranos V, O'Hare L, Baran JM, Cal JG, Lower EE, Engel PJ, Nathan SD. Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry Respiratory Medicine 139 (2018) 72–78
  • Khandhar SJ, Schatz CL, Collins DT, Graling PR, Rosner CM, Mahajan AK, Kiernan PD, Liu C, Fernando HC. Thoracic enhanced recovery with ambulation after surgery: a 6-year experience. Eur J Cardiothorac Surg. 2018 Mar 23
  • Aryal S, Nathan SD. Single vs. bilateral lung transplantation: when and why. Curr Opin Organ Transplant. 2018 Apr 7
  • Warren WA, Franco-Palacios D, King CS, Shlobin OA, Nathan SD, Katugaha SB, Mani H, Brown AW. A 24-Year-Old Woman with Precipitous Respiratory Failure After Lung Transplantation. Chest. 2018 Mar;153(3): e53-e56
  • Rodriguez LR, Emblom-Callahan M, Chhina M, Bui S, Aljeburry B, Tran LH, Novak R, Lemma M, Nathan SD, Grant GM. Global Gene Expression Analysis in an in vitro Fibroblast Model of Idiopathic Pulmonary Fibrosis Reveals Potential Role for CXCL14/CXCR4. Sci Rep. 2018 Mar 5;8(1):3983.
  • Yeo J, Morales DA, Chen T, Crawford EL, Zhang X, Blomquist TM, Levin AM, Massion PP, Arenberg DA, Midthun DE, Mazzone PJ, Nathan SD, Wainz RJ, Nana-Sinkam P, Willey PFS, Arend TJ, Padda K, Qiu S, Federov A, Hernandez DR, Hammersley JR, Yoon Y, Safi F, Khuder SA, Willey JC. RNAseq analysis of bronchial epithelial cells to identify COPD-associated genes and SNPs. BMC Pulm Med. 2018 Mar 5;18(1):42.
  • Cerbin LP, Ambrosy AP, Greene SJ, Armstrong PW, Butler J, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, Nathan, Mentz RJ. Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. JACC Heart Fail. 2018 Mar 7.
  • El-Chemaly S, O'Brien KJ, Nathan SD, Weinhouse GL, Goldberg HJ, Connors JM, Cui Y, Astor TL, Camp PC Jr., Rosas IO, Lemma M, Speransky V, Merideth MA, Gahl WA, Gochuico BR. Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation. PLoS One. 2018 Mar 16;13(3):e0194193
  • Agbor-Enoh S, Jackson AM, Tunc I, Berry GJ, Cochrane A, Grimm D, Davis A, Shah P, Brown AW, Wang Y, Timofte I, Shah P, Gorham S, Wylie J, Goodwin N, Jang MK, Marishta A, Bhatti K, Fideli U, Yang Y, Luikart H, Cao Z, Pirooznia M, Zhu J, Marboe C, Iacono A, Nathan SD, Orens J, Valantine HA, Khush K. Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis. J Heart Lung Transplant. 2018 Jan 31.
  • Jose A, Franco-Palacios D, King CS, Gomberg-Maitland M. A 70-Year-Old Woman Presenting with Diarrhea and In-hospital Cardiac Arrest. Chest. 2018 Jan;153(1):e5-e8.
  • Elinoff JM, Agarwal R, Barnett CF, Benza RL, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig EB, Shlobin OA, Steen VD, Zamanian RT, Solomon MA. Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. Am J Respir Crit Care Med. 2018 Feb 9.
  • Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev. 2017 Dec 6;26(146)
  • Baughman RP, Shlobin OA. Treatment of sarcoidosis-associated pulmonary hypertension: so close, and yet so far. Eur Respir J. 2017 Oct 19;50(4).
  • Brown AW, Nathan SD. The Value and Application of the Six Minute Walk Test in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017 Sep 21
  • Shlobin OA, Brown AW, Nathan SD. Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases.  Chest. 2017;151(1):204-214.
  • Mahajan AK, Folch E, Khandhar SJ, Channick CL, Santacruz JF, Mehta AC, Nathan SD. The Diagnosis and Management of Airway Complications Following Lung Transplantation. Ches 2017 Sep;152(3):627-638
  • Nathan SD, Martinez FJ. Pitfalls in developing new compounds for idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2017 Sep;23(5):426-431.
  • Shlobin OA, Baughman RP. Sarcoidosis-Associated Pulmonary Hypertension. Semin Respir Crit Care Med. 2017 Aug;38(4):450-462.
  • Shlobin OA, Baughman RP. Sarcoidosis-Associated Pulmonary Hypertension. Semin Respir Crit Care Med. 2017 Aug;38(4):450-462.
  • Nathan SD. Evaluating New Treatment Options, Am J Manag Care 2017 Jul; 23 (11 Suppl) S183-S190
  • Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L. Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670
  • Kaler M, Barochia AV, Weir NA, Cuento RA, Stylianou M, Roth MJ, Filie AC, Vaughey EC, Nathan SD, Levine SJ. A Randomized, Placebo-controlled, Double-blinded, Crossover Trial of Pioglitazone for Severe Asthma. J Allergy Clin Immunol. 2017 Jun 15.
  • Jose A, King CS, Shlobin OA, Kiernan JM, Cossa NA, Brown AW, Nathan SD. Ventricular diastolic pressure ratio as a marker of treatment response in pulmonary hypertension. Chest. 2017 May 17
  • King CS, Valentine V, Cattamanchi A, Franco-Palacios D, Shlobin OA, Brown AW, Singh R, Bogar L, Nathan SD. Early Post-Operative Management After Lung Transplantation: Results of an International Survey. Clin Transplant. 2017 Apr 20.
  • Mahajan AK, Folch E, Khandhar SJ, Channick CL, Santacruz JF, Mehta AC, Nathan SD. The Diagnosis and Management of Airway Complications Following Lung Transplantation. Chest. 2017 Mar 5.
  • Maher TM, Dejonckheere F, Nathan SD. Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension. J Manag Care Spec Pharm. 2017 Mar;23(3-b Suppl):S3-S4
  • Nathan SD, Behr J, Cottin V, Collard HR, Hoeper MM, Martinez FJ, Wells AU. Idiopathic interstitial pneumonia pulmonary hypertension: A target for therapy?  Respiratory Medicine 122 (2017): S10-S13 .
  • Fisher M, Nathan SD, Hill C, Marshall J, Dejonckheere F, Thuresson PO, Maher TM. Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis. J Manag Care Spec Pharm. 2017 Mar;23(3-b Suppl):S17-S24.
  • King CS, Nathan SD. Idiopathic Pulmonary Fibrosis: Impact and Optimal Management of Comorbidities. Lancet Respir Med. 2017 Jan;5(1):72-84.
  • Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzk DR, Daigl M, Kirchgaessler K, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Effect of Pirfenidone on Mortality: Pooled and Meta Analyses of Three Phase 3 IPF Clinical Trials. Lancet Respir Med. 2017 Jan;5(1):33-41
  • Shlobin OA, Brown AW, Nathan SD. Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. Chest. 2017;151(1):204-214.
  • Hong A, King C, A., Brown AWW, Ahmad S, Shlobin OA, Khandhar S, Bogar L, Rongione A, Nathan SD Hemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality. Multidisciplinary Respiratory Medicine 2016; 11:40-49
  • Nathan SD,Behr J, Cottin V, Collard HR, Hoeper MM, Martinez FJ, Wells AU.Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy? Respir Med. 2016 Nov 5.
  • Benza R, Mathai S, Nathan SD. sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension. Respir Med.2016 Nov 14
  • Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.Lancet Respir Med. 2016 Nov 19.
  • Brown AW, Kaya H, Nathan SD.Lung transplantation in IIP: A review. 2016 Oct;21(7):1173-84.
  • Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer,DJ, Nathan SD, Spirig D, Swigris JJ. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016 Sep;48(3):843-51.
  • Shlobin OA, Brown AW, Nathan SDPulmonary Hypertension in Diffuse Parenchymal Lung Diseases. 2016 Aug 20.
  • Fischer A, Denton CP, Matucci-Cerinic M, Gillies H, Blair C, Tislow J, Nathan SDAmbrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial. Respir Med. 2016 Aug; 117:254-63
  • King, CS, Nathan SPOINT: Should All Patients with Idiopathic Pulmonary Fibrosis, Even Those with More Than Moderate Impairment, Be Treated with Nintedanib or Pirfenidone? Yes. 2016 Aug;150(2):273-5
  • Anderson A, Shifren A, Nathan SDA safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin Drug Saf.2016 Jul;15(7):975-82.
  • King CS., Cochrane AB: The impact of early de novo donor specific antibodies on lung transplant outcomes: Is Timing Everything? Journal of Heart and Lung TransplantationJul 2016
  • Hassoun PM, Nathan SD.Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science. Eur Respir J. 2016 Jun;47(6):1615-7.
  • Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. 2016 May;71(5):429-35.
  • Shin S, King CS, Puri N, Shlobin OA, Brown AW, Ahmad S, Weir NA, Nathan SD.Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. Eur Respir J. 2016 May;47(5):1445-51.
  • Nathan SDAntacid therapy and idiopathic pulmonary fibrosis: cause for heartburn?Lancet Respir Med. 2016 May;4(5):340-1.
  • Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.BMJ Open Respir Res. 2016 Jan 12;3(1)
  • Crawford EL, Levin A, Safi F, Lu M, Baugh A, Zhang X, Yeo J, Khuder SA, Boulos AM, Nana-Sinkam P, Massion PP, Arenberg DA, Midthun D, Mazzone PJ, Nathan SD, Wainz R, Silvestri G, Tita J, Willey JC. Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository.BMC Pulm Med. 2016 Jan 22;16:16
  • Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.Eur Respir J. 2016 Jan;47(1):243-53
  • Nathan, Steven D, Brown, A Whitney, King, Christopher S.Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. Springer, 2016

Dr. Steven Nathan

  • King CS, Brown AW, Shlobin OA, Weir N, Libre M, Franco-Palacios D, Ahmad S, Nathan SD. Prevalence and Impact of WHO Group 3 Pulmonary Hypertension in Advanced Idiopathic Nonspecific Interstitial Pneumonia. Eur Respir J. 2018 May 17.
  • Aryal S, Nathan SD An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2018 May 8:1-14
  • Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS Kouranos V, O'Hare L, Baran JM, Cal JG, Lower EE, Engel PJ, Nathan SD. Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry Respiratory Medicine 139 (2018) 72–78
  • Aryal S, Nathan SD. Single vs. bilateral lung transplantation: when and why. Curr Opin Organ Transplant. 2018 Apr 7
  • Warren WA, Franco-Palacios D, King CS, Shlobin OA, Nathan SD, Katugaha SB, Mani H, Brown AW. A 24-Year-Old Woman with Precipitous Respiratory Failure After Lung Transplantation. Chest. 2018 Mar;153(3): e53-e56
  • Rodriguez LR, Emblom-Callahan M, Chhina M, Bui S, Aljeburry B, Tran LH, Novak R, Lemma M, Nathan SD, Grant GM. Global Gene Expression Analysis in an in vitro Fibroblast Model of Idiopathic Pulmonary Fibrosis Reveals Potential Role for CXCL14/CXCR4. Sci Rep. 2018 Mar 5;8(1):3983.
  • Yeo J, Morales DA, Chen T, Crawford EL, Zhang X, Blomquist TM, Levin AM, Massion PP, Arenberg DA, Midthun DE, Mazzone PJ, Nathan SD, Wainz RJ, Nana-Sinkam P, Willey PFS, Arend TJ, Padda K, Qiu S, Federov A, Hernandez DR, Hammersley JR, Yoon Y, Safi F, Khuder SA, Willey JC. RNAseq analysis of bronchial epithelial cells to identify COPD-associated genes and SNPs. BMC Pulm Med. 2018 Mar 5;18(1):42.
  • Cerbin LP, Ambrosy AP, Greene SJ, Armstrong PW, Butler J, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, Nathan, Mentz RJ. Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. JACC Heart Fail. 2018 Mar 7.
  • El-Chemaly S, O'Brien KJ, Nathan SD, Weinhouse GL, Goldberg HJ, Connors JM, Cui Y, Astor TL, Camp PC Jr., Rosas IO, Lemma M, Speransky V, Merideth MA, Gahl WA, Gochuico BR. Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation. PLoS One. 2018 Mar 16;13(3):e0194193
  • Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev. 2017Dec 6;26(146)
  • Brown AW, Nathan SD. The Value and Application of the Six Minute Walk Test in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017 Sep 21
  • Shlobin OA, Brown AW, Nathan SD. Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases.  Chest. 2017;151(1):204-214.
  • Mahajan AK, Folch E, Khandhar SJ, Channick CL, Santacruz JF, Mehta AC, Nathan SD. The Diagnosis and Management of Airway Complications Following Lung Transplantation. Ches 2017 Sep;152(3):627-638
  • Nathan SD, Martinez FJ. Pitfalls in developing new compounds for idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2017 Sep;23(5):426-431.
  • Shlobin OA, Baughman RP. Sarcoidosis-Associated Pulmonary Hypertension. Semin Respir Crit Care Med. 2017 Aug;38(4):450-462.
  • Nathan SD. Evaluating New Treatment Options, Am J Manag Care 2017 Jul; 23 (11 Suppl) S183-S190
  • Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L. Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670
  • Kaler M, Barochia AV, Weir NA, Cuento RA, Stylianou M, Roth MJ, Filie AC, Vaughey EC, Nathan SD, Levine SJ. A Randomized, Placebo-controlled, Double-blinded, Crossover Trial of Pioglitazone for Severe Asthma. J Allergy Clin Immunol. 2017 Jun 15.
  • Jose A, King CS, Shlobin OA, Kiernan JM, Cossa NA, Brown AW, Nathan SD. Ventricular diastolic pressure ratio as a marker of treatment response in pulmonary hypertension. Chest. 2017 May 17
  • King CS, Valentine V, Cattamanchi A, Franco-Palacios D, Shlobin OA, Brown AW, Singh R, Bogar L, Nathan SD. Early Post-Operative Management After Lung Transplantation: Results of an International Survey. Clin Transplant. 2017 Apr 20.
  • Mahajan AK, Folch E, Khandhar SJ, Channick CL, Santacruz JF, Mehta AC, Nathan SD. The Diagnosis and Management of Airway Complications Following Lung Transplantation. Chest. 2017 Mar 5.
  • Maher TM, Dejonckheere F, Nathan SD. Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension. J Manag Care Spec Pharm. 2017 Mar;23(3-b Suppl):S3-S4
  • Nathan SD, Behr J, Cottin V, Collard HR, Hoeper MM, Martinez FJ, Wells AU. Idiopathic interstitial pneumonia pulmonary hypertension: A target for therapy?  Respiratory Medicine 122 (2017): S10-S13 .
  • Fisher M, Nathan SD, Hill C, Marshall J, Dejonckheere F, Thuresson PO, Maher TM. Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis. J Manag Care Spec Pharm. 2017 Mar;23(3-b Suppl):S17-S24.
  • King CS, Nathan SD. Idiopathic Pulmonary Fibrosis: Impact and Optimal Management of Comorbidities. Lancet Respir Med. 2017 Jan;5(1):72-84.
  • Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzk DR, Daigl M, Kirchgaessler K, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Effect of Pirfenidone on Mortality: Pooled and Meta Analyses of Three Phase 3 IPF Clinical Trials. Lancet Respir Med. 2017 Jan;5(1):33-41
  • Hong A, King C, A., Brown AWW, Ahmad S, Shlobin OA, Khandhar S, Bogar L, Rongione A, Nathan SD Hemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality. Multidisciplinary Respiratory Medicine 2016; 11:40-49
  • Nathan SD,Behr J, Cottin V, Collard HR, Hoeper MM, Martinez FJ, Wells AU.Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy? Respir Med. 2016 Nov 5.
  • Benza R, Mathai S, Nathan SD. sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension. Respir Med.2016 Nov 14
  • Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.Lancet Respir Med. 2016 Nov 19.
  • Brown AW, Kaya H, Nathan SD.Lung transplantation in IIP: A review. 2016 Oct;21(7):1173-84.
  • Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer,DJ, Nathan SD, Spirig D, Swigris JJ. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016 Sep;48(3):843-51.
  • Shlobin OA, Brown AW, Nathan SDPulmonary Hypertension in Diffuse Parenchymal Lung Diseases. 2016 Aug 20.
  • Fischer A, Denton CP, Matucci-Cerinic M, Gillies H, Blair C, Tislow J, Nathan SDAmbrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial. Respir Med. 2016 Aug; 117:254-63
  • King, CS, Nathan SPOINT: Should All Patients with Idiopathic Pulmonary Fibrosis, Even Those with More Than Moderate Impairment, Be Treated with Nintedanib or Pirfenidone? Yes. 2016 Aug;150(2):273-5
  • Anderson A, Shifren A, Nathan SDA safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin Drug Saf.2016 Jul;15(7):975-82.
  • Hassoun PM, Nathan SD.Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science. Eur Respir J. 2016 Jun;47(6):1615-7.
  • Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. 2016 May;71(5):429-35.
  • Shin S, King CS, Puri N, Shlobin OA, Brown AW, Ahmad S, Weir NA, Nathan SD.Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. Eur Respir J. 2016 May;47(5):1445-51.
  • Nathan SDAntacid therapy and idiopathic pulmonary fibrosis: cause for heartburn?Lancet Respir Med. 2016 May;4(5):340-1.
  • Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.BMJ Open Respir Res. 2016 Jan 12;3(1)
  • Crawford EL, Levin A, Safi F, Lu M, Baugh A, Zhang X, Yeo J, Khuder SA, Boulos AM, Nana-Sinkam P, Massion PP, Arenberg DA, Midthun D, Mazzone PJ, Nathan SD, Wainz R, Silvestri G, Tita J, Willey JC. Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository.BMC Pulm Med. 2016 Jan 22;16:16
  • Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.Eur Respir J. 2016 Jan;47(1):243-53
  • Nathan, Steven D, Brown, A Whitney, King, Christopher S.Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. Springer, 2016

Dr. A. Whitney Walter Brown

  • Brown AW. Unclassifiable Interstitial Lung Disease: Time to Shrink the Black Box. Ann Am Thorac Soc. 2018 Jul;15(7):806-807.
  • King CS, Brown AW, Shlobin OA, Weir N, Libre M, Franco-Palacios D, Ahmad S, Nathan SD. Prevalence and Impact of WHO Group 3 Pulmonary Hypertension in Advanced Idiopathic Nonspecific Interstitial Pneumonia. Eur Respir J. 2018 May 17.
  • Warren WA, Franco-Palacios D, King CS, Shlobin OA, Nathan SD, Katugaha SB, Mani H, Brown AW. A 24-Year-Old Woman with Precipitous Respiratory Failure After Lung Transplantation. Chest. 2018 Mar;153(3): e53-e56
  • Agbor-Enoh S, Jackson AM, Tunc I, Berry GJ, Cochrane A, Grimm D, Davis A, Shah P, Brown AW, Wang Y, Timofte I, Shah P, Gorham S, Wylie J, Goodwin N, Jang MK, Marishta A, Bhatti K, Fideli U, Yang Y, Luikart H, Cao Z, Pirooznia M, Zhu J, Marboe C, Iacono A, Nathan SD, Orens J, Valantine HA, Khush K. Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis. J Heart Lung Transplant. 2018 Jan 31.
  • Shlobin OA, Brown AW, Nathan SD. Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. Chest. 2017;151(1):204-214.
  • Brown AW, Nathan SD. The Value and Application of the Six Minute Walk Test in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017 Sep 21
  • Jose A, King CS, Shlobin OA, Kiernan JM, Cossa NA, Brown AW, Nathan SD. Ventricular diastolic pressure ratio as a marker of treatment response in pulmonary hypertension. Chest. 2017 May 17
  • King CS, Valentine V, Cattamanchi A, Franco-Palacios D, Shlobin OA, Brown AW, Singh R, Bogar L, Nathan SD. Early Post-Operative Management After Lung Transplantation: Results of an International Survey. Clin Transplant. 2017 Apr 20.
  • Shin S, King CS, Puri N, Shlobin OA, Brown AW, Ahmad S, Weir NA, Nathan SDPulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. Eur Respir J. 2016 May;47(5):1445-51.
  • Shlobin OA, Brown AW, Nathan SDPulmonary Hypertension in Diffuse Parenchymal Lung Diseases. 2016 Aug 20.
  • Nathan, Steven D, Brown, A Whitney, King, Christopher SGuide to Clinical Management of Idiopathic Pulmonary Fibrosis. Springer,2016
  • Hong A, King C, A., Brown AWW, Ahmad S, Shlobin OA, Khandhar S, Bogar L, Rongione A, Nathan SDHemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality. Multidisciplinary Respiratory Medicine, 2016; 11:40-49
  • Brown AW, Kaya H, Nathan SD. Lung transplantation in IIP: A review.  2016 Oct;21(7):1173-84.

Dr. Christopher King

  • King CS, Brown AW, Shlobin OA, Weir N, Libre M, Franco-Palacios D, Ahmad S, Nathan SD. Prevalence and Impact of WHO Group 3 Pulmonary Hypertension in Advanced Idiopathic Nonspecific Interstitial Pneumonia. Eur Respir J. 2018 May 17.
  • Warren WA, Franco-Palacios D, King CS, Shlobin OA, Nathan SD, Katugaha SB, Mani H, Brown AW. A 24-Year-Old Woman with Precipitous Respiratory Failure After Lung Transplantation. Chest. 2018 Mar;153(3): e53-e56
  • Jose A, Franco-Palacios D, King CS, Gomberg-Maitland M. A 70-Year-Old Woman Presenting with Diarrhea and In-hospital Cardiac Arrest. Chest. 2018 Jan;153(1):e5-e8.
  • Jose A, King CS, Shlobin OA, Kiernan JM, Cossa NA, Brown AW, Nathan SD. Ventricular diastolic pressure ratio as a marker of treatment response in pulmonary hypertension. Chest. 2017 May 17
  • King CS, Valentine V, Cattamanchi A, Franco-Palacios D, Shlobin OA, Brown AW, Singh R, Bogar L, Nathan SD. Early Post-Operative Management After Lung Transplantation: Results of an International Survey. Clin Transplant. 2017 Apr 20.
  • King CS, Nathan SD. Idiopathic Pulmonary Fibrosis: Impact and Optimal Management of Comorbidities. Lancet Respir Med. 2017 Jan;5(1):72-84.
  • Hong A, King C, A., Brown AWW, Ahmad S, Shlobin OA, Khandhar S, Bogar L, Rongione A, Nathan SDHemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality. Multidisciplinary Respiratory Medicine. 2016; 11:40-49
  • King CS, Nathan SD.Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2016 Sep 2.
  • King, CS, Nathan SPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Chest. 2016 Aug;150(2):273-5
  • King CS., Cochrane AB: The impact of early de novo donor specific antibodies on lung transplant outcomes: Is Timing Everything? Journal of Heart and Lung TransplantationJul 2016
  • Shin S, King CS, Puri N, Shlobin OA, Brown AW, Ahmad S, Weir NA, Nathan SDPulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. Eur Respir J. 2016 May;47(5):1445-51.
  • Nathan, Steven D, Brown, A Whitney, King, Christopher SGuide to Clinical Management of Idiopathic Pulmonary Fibrosis.Springer,2016

Dr. Oksana Shlobin

  • King CS, Brown AW, Shlobin OA, Weir N, Libre M, Franco-Palacios D, Ahmad S, Nathan SD. Prevalence and Impact of WHO Group 3 Pulmonary Hypertension in Advanced Idiopathic Nonspecific Interstitial Pneumonia. Eur Respir J. 2018 May 17.
  • Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS Kouranos V, O'Hare L, Baran JM, Cal JG, Lower EE, Engel PJ, Nathan SD. Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. Respiratory Medicine 139 (2018) 72–78.
  • Warren WA, Franco-Palacios D, King CS, Shlobin OA, Nathan SD, Katugaha SB, Mani H, Brown AW. A 24-Year-Old Woman with Precipitous Respiratory Failure After Lung Transplantation. Chest. 2018 Mar;153(3): e53-e56
  • Elinoff JM, Agarwal R, Barnett CF, Benza RL, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig EB, Shlobin OA, Steen VD, Zamanian RT, Solomon MA. Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. Am J Respir Crit Care Med. 2018 Feb 9.
  • Baughman RP, Shlobin OA. Treatment of sarcoidosis-associated pulmonary hypertension: so close, and yet so far. Eur Respir J. 2017 Oct 19;50(4).
  • Shlobin OA, Baughman RP. Sarcoidosis-Associated Pulmonary Hypertension. Semin Respir Crit Care Med. 2017 Aug;38(4):450-462.
  • Shlobin OA, Brown AW, Nathan SD. Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases.  Chest. 2017;151(1):204-214.
  • Jose A, King CS, Shlobin OA, Kiernan JM, Cossa NA, Brown AW, Nathan SD. Ventricular diastolic pressure ratio as a marker of treatment response in pulmonary hypertension. Chest. 2017 May 17
  • King CS, Valentine V, Cattamanchi A, Franco-Palacios D, Shlobin OA, Brown AW, Singh R, Bogar L, Nathan SD. Early Post-Operative Management After Lung Transplantation: Results of an International Survey. Clin Transplant. 2017 Apr 20.
  • Hong A, King C, A., Brown AWW, Ahmad S, Shlobin OA, Khandhar S, Bogar L, Rongione A, Nathan SDHemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality. Multidisciplinary Respiratory Medicine, 2016; 11:40-49
  • Shlobin OA, Brown AW, Nathan SDPulmonary Hypertension in Diffuse Parenchymal Lung Diseases.Chest, 2016 Aug 20.
  • Shin S, King CS, Puri N, Shlobin OA, Brown AW, Ahmad S, Weir NA, Nathan SDPulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis.Eur Respir J. 2016 May;47(5):1445-51.